Leukemia

New opportunity to treat drug-resistant leukemia discovered

New opportunity to treat drug-resistant leukemia discovered

By

A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipients

By

A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.

Test predicts response to treatment for graft-versus-host disease (GVHD)

By

A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.

Risk for leukemia after treatment for early stage breast cancer higher than reported

By

According to results of a new, retrospective study, the risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer is double that previously reported.

Oral inhibitor shows clinical activity in poor-prognosis acute myelogenous leukemia (AML)

By

An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.

New kind of targeted drug is promising for patients with leukemia

New kind of targeted drug is promising for patients with leukemia

By

Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.

Investigational cellular therapy promising for pediatric ALL and for lymphoma

By

Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.

Breast cancer treatment-related leukemia risk higher than thought

Breast cancer treatment-related leukemia risk higher than thought

Among early-stage breast cancer patients who undergo chemotherapy and/or radiation treatment, the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought.

Blincyto now FDA-approved for precursor B-cell acute lymphoblastic leukemia

Blincyto now FDA-approved for precursor B-cell acute lymphoblastic leukemia

The drug, which spurs the body's immune system, has now been approved to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL).

For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease

For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease

Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.

Good news for young patients with a leukemia subtype with poor prognosis

Good news for young patients with a leukemia subtype with poor prognosis

By

For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.

Novel drug safe for patients with leukemia

Novel drug safe for patients with leukemia

By

Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.

For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective

For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective

Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).

High-risk leukemia subtype becomes more common with age

High-risk leukemia subtype becomes more common with age

By

Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.

Weekend hospitalization linked to longer stays for pediatric patients with leukemia

By

Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.

CPI-613 safe and somewhat efficacious for patients with leukemia

CPI-613 safe and somewhat efficacious for patients with leukemia

CPI-613 safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia.

Natural killer cells battle pediatric leukemia

Natural killer cells battle pediatric leukemia

A select team of immune-system cells from patients with leukemia can be multiplied in the laboratory, creating a horde of natural killer cells that can be used to target and destroy the cancer cells.

Major breakthrough in understanding acute lymphoblastic leukemia

Major breakthrough in understanding acute lymphoblastic leukemia

By

By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.

Pediatric patients with leukemia have longer stay if admitted on weekend

Pediatric patients with leukemia have longer stay if admitted on weekend

Weekend admission for pediatric patients with leukemia associated with a longer length of stay.

Study explores reasons for significant variations in blood cancer survival across Europe

Study explores reasons for significant variations in blood cancer survival across Europe

The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.

New test predicts survival in patients with leukemia

New test predicts survival in patients with leukemia

Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukemia.

US Food and Drug Administration fast-tracks novel leukemia therapy

US Food and Drug Administration fast-tracks novel leukemia therapy

An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.

Game changer for leukemia therapy

Game changer for leukemia therapy

By

Cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment, according to a new study.

Restoring gene function reverses cancer in common childhood leukemia

Restoring gene function reverses cancer in common childhood leukemia

Researchers in Melbourne, Australia, have shown that switching off a gene called Pax5 could cause a type of leukemia, and restoring its function could cure the disease.

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs